北五味子乙素提取纯化及生物活性研究
|
摘要
五味子含有多种营养成分,是一种具有很大开发前景的药食兼用植物。五味子中的主要活性物质是木脂素,而五味子乙素在五味子木脂素中含量较高,是主要的功能成分。目前研究发现,五味子乙素具有很强的抗氧化性和清除自由基作用,能够预防阿霉素引起的心脏毒性,其脂质体作为药物新型剂,能够提高药物的靶向性,降低药物毒性。
本文以辽宁产北五味子为原料,通过正交实验研究了五味子中功能性成分五味子乙素的提取方法,采用大孔树脂法进行纯化,并在此基础上对五味子乙素提取液的清除自由基、抑菌作用进行初步研究；研究了五味子乙素脂质体和五味子乙素—阿霉素脂质体的制备工艺；对制备的五味子乙素脂质体进行了理化性质研究；对五味子乙素—阿霉素脂质体进行了理化性质、药动力学特性进行了研究；对五味子乙素的抗肿瘤作用进行了初步研究。主要研究结果如下：
1.溶剂法提取五味子乙素条件为：溶剂浓度90%,液料比7：1,处理时间2.5h,次数3次：超临界CO2提取五味子乙素条件为：压力30 Mpa,温度40℃,粒度40目,时间2.0h；微波辅助提取五味子乙素条件为：微波功率为500 w,液料比为10：1,处理时间为8 min；超声波提取五味子乙素条件为：超声波功率180W,液料比为10：1,处理时间为40min。
2.实验中所用的树脂中,AB-8树脂的吸附和解吸能力都最强,适宜于五味子乙素的分离纯化。用AB-8树脂分离纯化五味子提取物时,其工艺参数为：上样浓度0.09mgmL-上样流速为1.0 mL.min-1,静态吸附时间为150mmin,解吸流速为0.5 mL.min-1。
3.采用旋转蒸发薄膜法制备五味子乙素脂质体。通过单因素及正交试验,确定最佳制备工艺为：大豆磷脂与胆固醇质量比为1：0.1,五味子乙素载量1%,旋转蒸发温度为65℃,pH值为6.9。在此条件下,五味子乙素脂质体的粒度分布为70～200 nm,平均粒径值为(132.5士19.6)nm(n=3),Zeta电位为(-37.3±2.5)mV,包封率为92.4%。
4.采用旋转蒸发薄膜法制备五味子乙素—阿霉素脂质体。取五味子乙素为0.2g时,通过单因素及其正交试验确定最佳制备工艺为：大豆磷脂与胆固醇的比为1：0.05,大豆磷脂与阿霉素的比为2：0.01,旋转蒸发温度为60℃,pH值为7.4。在此条件下制备的五味子乙素-阿霉素脂质体粒度小,包封率高。粒度分布为50～200 nm,平均粒径值为(135.2±19.6)nm(n=3),Zeta电位为(-38.6±2.5)mV,包封率为96.45%。五味子乙素-阿霉素脂质体的药动力学试验结果表明,五味子乙素-阿霉素脂质体能够提高阿霉素的血浆药物浓度,延长药物在血液的停留时间,以获得更充足的时间到达靶向部位,提高治疗效果。
5.急性毒性试验结果：五味子乙素-阿霉素脂质体LD50=52.8mg/kg,阿霉素脂质体LD50=41.5mg/kg,阿霉素LD50=18.2mg/kg。由此可初步得知,五味子乙素—阿霉素脂质体能够降低阿霉素的毒性。采用动物S-180实体肿瘤模型,采用尾静脉注射给药法,对五味子乙素的抗肿瘤作用进行了初步研究。结果表明,本试验制备的五味子乙素脂质体抗肿瘤作用并不显著,制备的五味子乙素—阿霉素脂质体的抗肿瘤效果比较显著。
6.五味子乙素提取液对自由基的清除效果明显,其中对.OH清除作用大于相同浓度的Vc,其半数清除浓度为0.2 mg.mL-1；对O2·-清除作用小于Vc,其半数清除浓度为0.24 mg.mL-1。五味子乙素提取液对金黄色葡萄球菌、白色念珠菌、沙门氏菌、大肠杆菌、枯草芽孢杆菌均有一定的抑制作用,其中对白色念珠菌和金黄色葡萄球菌的抑制作用最强,最低抑菌浓度为0.25 mg.mL-1,对根霉、黑曲霉、南阳酵母无明显抑菌活性。
Schisandra chinensis(Turcz.)Baill has variety of nutrients. It is a good development prospects plant with the use of drug and eating. Lignan which is the main active ingredient of Schisandra chinensis has a high content ofγ-schizandrin. The main functional component isγ-schizandrin. Modern research has shown thatγ-schizandrin has cancer-fighting doxorubicin and scavenging free radicals role. The principal active ingredient are lignan and polysacch-aride. Liposomes as a drug of new agents that can improve drug targeting and reduce drug toxicity.
This subject took Schisandra chinensis which was collected in Liao Ning province as material, studied the extract method ofγ-schizandrin by using orthogonal test design, macroporous resin were employed forγ-schizandrin separation and purification. The antioxidant and antimicrobial activities of the extract were also investigated. This study investigated the preparation of theγ-schizandrin liposomes and theγ-schizandrin-doxorubicin liposomes. Research the Physical and Chemical Properties ofγ-schizandrin liposomes, the Physical and Chemical Properties ofγ-schizandrin-doxorubicin liposomes, the drug kinetics. Preliminary study the anti-tumor effect ofγ-schizandrin. The main results were shown as follows:
1.The optimum technological conditions of solvent extraction:solvent strength 90%, Liquid:Materal 7:1, processing time 2.5h, extract 3 times; The optimum technological conditions of supercritical CO2 extraction:pressure 30Mpa, temperature 40℃, granularity 40 mesh, time 2h; The optimum extraction conditions of microwave assisted extraction were as follows:power 500 W, solvent-material ratio 10:1, extraction time 8min; The optimum extraction conditions of ultrasonic waves:power180 W, solvent-material ratio 10:1, extraction time 40min.
2.AB-8 resin is suitable forγ-schizandrin separation and purification with better capabilities of absorption and desorption in the research. The technological parameters of AB-8 edulcorateγ-schizandrin:concentration ofγ-schizandrin 0.09mg·mL-1; absorption flow rate 1mL·min-1; absorption time 150min; elution rate of 0.5 mL·min-1.
3.Adopts rotating evaporation film for offering legal liposomes. Edible with encasulation efficiency as evaluation indexes. By single factor and orthogonal test, for optimum technological conditions 1:0.1,γ-schizandrin grain cindoruk 1%, Rotating evaporation temperature for 60℃, pH 6.9, encapsulation rates 92.4%.
4. Prepared by rotating evaporation film legalγ-schizandrin -doxorubicin liposomes. The best preparation process for:Soybean lecithin and cholesterol than for the 1:0.05, Soybean lecithin and than for the adriamycin 2:0.01. In rotating evaporation temperature for 60℃conditions and pH= 7.4. This method of the preparation of fructusγ-schizandrin element of liposomes doxorubicin particle distribution of 50～200 nm. Average particle size value is (135.2±19.6) nm (n=3). Measured by flocculation separation fructusγ-schizandrin doxorubicin liposomes encapsulation efficiency can reach(96.45±1.86)%, Zeta Potential for(-38.6±2.5) mV. Results show that fructusγ-schizandrin doxorubicin can significantly improve the liposome drug concentration of plasma adriamycin. Fructus schisandrae meal can enhance the party of adriamycin, efficacy, together they can prolong drug use in the retention period of blood, to get plenty of time to get to target sites, increases healing done.
5. For acute toxicity tests, fructus schisandrae b grain doxorubicin liposomes LD50=52.8 mg/kg, Doxorubicin liposomes LD50= 41.5 mg/kg, Doxorubicin LD50= 1.82 mg/kg. We can see that, Fructusγ-schizandrin to significantly reduce the toxicity of adriamycin. Using animal S-180 solid tumors model, adopt tail intravenous drug laws fructusγ-schizandrin doxorubicin liposomes anti-tumor effect. Results show that, Meat and edible bliposome fructusγ-schizandrin element has certain antitumor function but not significant, doxorubicin liposomes compared with adriamycin, Cancer-fighting improve also was not significant. But fructusγ-schizandrin doxorubicin anti-cancer effects of liposomes significantly higher than doxorubicin.
6.γ-schizandrin extract had effective scavenging scavenging effect of.OH more than the same concentration of Vc, the IC50 is 0.2 mg.mL-1, scavenging effect of O2.- less than Vc, the IC50 is 0.24 mg.mL-1.γ-schizandrin extract against Staphylococcus aureus, Candida albicans, Salmonella, E. coli, Bacillus subtilis has a certain extent, of which Candida albicans and Staphylococcus aureus in the strongest inhibition, minimum inhibitory concentration of 0.25 mg.mL-1; on Rhizopus, Aspergillus niger, Nanyang yeast had no significant antibacterial activity.
本文以辽宁产北五味子为原料,通过正交实验研究了五味子中功能性成分五味子乙素的提取方法,采用大孔树脂法进行纯化,并在此基础上对五味子乙素提取液的清除自由基、抑菌作用进行初步研究；研究了五味子乙素脂质体和五味子乙素—阿霉素脂质体的制备工艺；对制备的五味子乙素脂质体进行了理化性质研究；对五味子乙素—阿霉素脂质体进行了理化性质、药动力学特性进行了研究；对五味子乙素的抗肿瘤作用进行了初步研究。主要研究结果如下：
1.溶剂法提取五味子乙素条件为：溶剂浓度90%,液料比7：1,处理时间2.5h,次数3次：超临界CO2提取五味子乙素条件为：压力30 Mpa,温度40℃,粒度40目,时间2.0h；微波辅助提取五味子乙素条件为：微波功率为500 w,液料比为10：1,处理时间为8 min；超声波提取五味子乙素条件为：超声波功率180W,液料比为10：1,处理时间为40min。
2.实验中所用的树脂中,AB-8树脂的吸附和解吸能力都最强,适宜于五味子乙素的分离纯化。用AB-8树脂分离纯化五味子提取物时,其工艺参数为：上样浓度0.09mgmL-上样流速为1.0 mL.min-1,静态吸附时间为150mmin,解吸流速为0.5 mL.min-1。
3.采用旋转蒸发薄膜法制备五味子乙素脂质体。通过单因素及正交试验,确定最佳制备工艺为：大豆磷脂与胆固醇质量比为1：0.1,五味子乙素载量1%,旋转蒸发温度为65℃,pH值为6.9。在此条件下,五味子乙素脂质体的粒度分布为70～200 nm,平均粒径值为(132.5士19.6)nm(n=3),Zeta电位为(-37.3±2.5)mV,包封率为92.4%。
4.采用旋转蒸发薄膜法制备五味子乙素—阿霉素脂质体。取五味子乙素为0.2g时,通过单因素及其正交试验确定最佳制备工艺为：大豆磷脂与胆固醇的比为1：0.05,大豆磷脂与阿霉素的比为2：0.01,旋转蒸发温度为60℃,pH值为7.4。在此条件下制备的五味子乙素-阿霉素脂质体粒度小,包封率高。粒度分布为50～200 nm,平均粒径值为(135.2±19.6)nm(n=3),Zeta电位为(-38.6±2.5)mV,包封率为96.45%。五味子乙素-阿霉素脂质体的药动力学试验结果表明,五味子乙素-阿霉素脂质体能够提高阿霉素的血浆药物浓度,延长药物在血液的停留时间,以获得更充足的时间到达靶向部位,提高治疗效果。
5.急性毒性试验结果：五味子乙素-阿霉素脂质体LD50=52.8mg/kg,阿霉素脂质体LD50=41.5mg/kg,阿霉素LD50=18.2mg/kg。由此可初步得知,五味子乙素—阿霉素脂质体能够降低阿霉素的毒性。采用动物S-180实体肿瘤模型,采用尾静脉注射给药法,对五味子乙素的抗肿瘤作用进行了初步研究。结果表明,本试验制备的五味子乙素脂质体抗肿瘤作用并不显著,制备的五味子乙素—阿霉素脂质体的抗肿瘤效果比较显著。
6.五味子乙素提取液对自由基的清除效果明显,其中对.OH清除作用大于相同浓度的Vc,其半数清除浓度为0.2 mg.mL-1；对O2·-清除作用小于Vc,其半数清除浓度为0.24 mg.mL-1。五味子乙素提取液对金黄色葡萄球菌、白色念珠菌、沙门氏菌、大肠杆菌、枯草芽孢杆菌均有一定的抑制作用,其中对白色念珠菌和金黄色葡萄球菌的抑制作用最强,最低抑菌浓度为0.25 mg.mL-1,对根霉、黑曲霉、南阳酵母无明显抑菌活性。
Schisandra chinensis(Turcz.)Baill has variety of nutrients. It is a good development prospects plant with the use of drug and eating. Lignan which is the main active ingredient of Schisandra chinensis has a high content ofγ-schizandrin. The main functional component isγ-schizandrin. Modern research has shown thatγ-schizandrin has cancer-fighting doxorubicin and scavenging free radicals role. The principal active ingredient are lignan and polysacch-aride. Liposomes as a drug of new agents that can improve drug targeting and reduce drug toxicity.
This subject took Schisandra chinensis which was collected in Liao Ning province as material, studied the extract method ofγ-schizandrin by using orthogonal test design, macroporous resin were employed forγ-schizandrin separation and purification. The antioxidant and antimicrobial activities of the extract were also investigated. This study investigated the preparation of theγ-schizandrin liposomes and theγ-schizandrin-doxorubicin liposomes. Research the Physical and Chemical Properties ofγ-schizandrin liposomes, the Physical and Chemical Properties ofγ-schizandrin-doxorubicin liposomes, the drug kinetics. Preliminary study the anti-tumor effect ofγ-schizandrin. The main results were shown as follows:
1.The optimum technological conditions of solvent extraction:solvent strength 90%, Liquid:Materal 7:1, processing time 2.5h, extract 3 times; The optimum technological conditions of supercritical CO2 extraction:pressure 30Mpa, temperature 40℃, granularity 40 mesh, time 2h; The optimum extraction conditions of microwave assisted extraction were as follows:power 500 W, solvent-material ratio 10:1, extraction time 8min; The optimum extraction conditions of ultrasonic waves:power180 W, solvent-material ratio 10:1, extraction time 40min.
2.AB-8 resin is suitable forγ-schizandrin separation and purification with better capabilities of absorption and desorption in the research. The technological parameters of AB-8 edulcorateγ-schizandrin:concentration ofγ-schizandrin 0.09mg·mL-1; absorption flow rate 1mL·min-1; absorption time 150min; elution rate of 0.5 mL·min-1.
3.Adopts rotating evaporation film for offering legal liposomes. Edible with encasulation efficiency as evaluation indexes. By single factor and orthogonal test, for optimum technological conditions 1:0.1,γ-schizandrin grain cindoruk 1%, Rotating evaporation temperature for 60℃, pH 6.9, encapsulation rates 92.4%.
4. Prepared by rotating evaporation film legalγ-schizandrin -doxorubicin liposomes. The best preparation process for:Soybean lecithin and cholesterol than for the 1:0.05, Soybean lecithin and than for the adriamycin 2:0.01. In rotating evaporation temperature for 60℃conditions and pH= 7.4. This method of the preparation of fructusγ-schizandrin element of liposomes doxorubicin particle distribution of 50～200 nm. Average particle size value is (135.2±19.6) nm (n=3). Measured by flocculation separation fructusγ-schizandrin doxorubicin liposomes encapsulation efficiency can reach(96.45±1.86)%, Zeta Potential for(-38.6±2.5) mV. Results show that fructusγ-schizandrin doxorubicin can significantly improve the liposome drug concentration of plasma adriamycin. Fructus schisandrae meal can enhance the party of adriamycin, efficacy, together they can prolong drug use in the retention period of blood, to get plenty of time to get to target sites, increases healing done.
5. For acute toxicity tests, fructus schisandrae b grain doxorubicin liposomes LD50=52.8 mg/kg, Doxorubicin liposomes LD50= 41.5 mg/kg, Doxorubicin LD50= 1.82 mg/kg. We can see that, Fructusγ-schizandrin to significantly reduce the toxicity of adriamycin. Using animal S-180 solid tumors model, adopt tail intravenous drug laws fructusγ-schizandrin doxorubicin liposomes anti-tumor effect. Results show that, Meat and edible bliposome fructusγ-schizandrin element has certain antitumor function but not significant, doxorubicin liposomes compared with adriamycin, Cancer-fighting improve also was not significant. But fructusγ-schizandrin doxorubicin anti-cancer effects of liposomes significantly higher than doxorubicin.
6.γ-schizandrin extract had effective scavenging scavenging effect of.OH more than the same concentration of Vc, the IC50 is 0.2 mg.mL-1, scavenging effect of O2.- less than Vc, the IC50 is 0.24 mg.mL-1.γ-schizandrin extract against Staphylococcus aureus, Candida albicans, Salmonella, E. coli, Bacillus subtilis has a certain extent, of which Candida albicans and Staphylococcus aureus in the strongest inhibition, minimum inhibitory concentration of 0.25 mg.mL-1; on Rhizopus, Aspergillus niger, Nanyang yeast had no significant antibacterial activity.
引文
1.包天桐,徐桂芳,刘耕陶.1979.五味子仁七种成分的一些药理作用比较,药学学报,14(1)：1.
2.常向明,刘小平,姚垂宇,等.1995.香连丸联用TMP抗菌作用的实验研究[J].中国药房,6(4)：16-17.
3.常向明,姚垂宇,刘小平,等.1994.黄连联用TMP抗菌作用的实验研究[J].中国中药杂志,19(12)：748-750.
4.陈斯泽,汪森明,张积仁.2008.盐酸洛拉曲克长循环脂质体制备及其抑瘤特性研究[J].南方医科大学学报,3：403-405
5.陈业高,秦国伟,谢毓元.2001.五味子科植物木脂素成分的化学[J].化学世界,(7)：44-47.
6.程国强,冯年平,唐琦文,等.2001.黄芩苷对眼科常见病原菌的体外抗菌作用[J].中国医院药学杂志,21(6)：347-348.
7.戴好富,周俊,彭再刚,等.2000.北五味子的水溶性化学成分[J].天然产物研究与开发,13(1)：24-26.
8.邓胜国,邓泽元,黄丽.2006.荷叶黄酮体外抗氧化活性的研究[J].食品科技,7：274.
9.邓英杰,史淑芬,顾学裘.1988.油酸多相脂质体注射液包封率测定方法的研究[J].药学学报,23(7)：534-544.
10.丁劲松,杨敏,陈琼.2004.聚乙二醇衍生化磷脂与脂质体立体稳定性[J].中国医药工业杂志,35(1)：55-58.
11.范健,文旭,缪玉山.2001.脂质体阿霉素与游离阿霉素在大鼠体内药代动力学中国药科大学学报,32(5)：354-358
12.付绍平,张峰,张慧,等.2004.反相高效液相色谱法测定五味子中木脂素的含量[J].现代中药研究与实践,(18)：32-34.
13.高建平,王彦涵,郁韵秋,等.2003.南五味子木脂素成分的HPLC含量测定及其变异规律[J].中国天然药物,1(2)：89-93.
14.高普军,朴云峰,郭晓琳.1995.北五味子粗多糖保肝作用的机理[J].白求恩医科大学学报,21(2)：147-148.
15.高普军,朴云峰,郭晓琳.1995.北五味子粗多糖保肝作用的机理[J].白求恩医科大学学报,21(2)：147-148.
16.高荣海等.2006.大孔吸附树脂对大豆异黄酮吸附性能的研究,研究与探讨[J],27(10)：49-51.
17.高思海,潘铁成,李平.2004.五味子酚对大鼠心脏移植供心的保护作用研究[J].中华实用中西医杂 志,4(17)：1-3.
18.高晔珩,宋小妹,冯改利.2005.不同产地南五味子质量分析研究[J].陕西中医,26(8)：836-837.
19.关洪全,李海波,李建春,等.2000.生姜与乳酸协同对食品防腐作用的基础研究[J].中国中医药信息杂志,7(2)：27-28.
20.郭春梅.2003.不同产地的五味子中五味子乙素含量测定[J].黑龙江医药,16(1)：6-7.
21.韩学君,王发善.2003.北五味子有效成分的高效液相层析测定[J].黑龙江医药科学,26(4)：104.
22.韩止洲,李亚凤.1997.南、北五味子的薄层色谱鉴别及定量分析[J].时珍国药研究,8(4)：334-335.
23.郝金玉.2001.微波萃取除虫菊酯[J].精细石油化工,(2)：47-49.
24.郝书文,宋桂娥.2003.北五味子果梗的药用研究[J].山东医药工业,22(2)：8-9.
25.何来英,冯晓莲,孙明,等.2004.五味子的急性毒性和遗传毒性研究[J].1 1(4)：645-648.
26.胡博路,孟洁,胡迎芬.2000.30种中草药清除自由基的研究[J].青岛大学学报,13(2)：38.
27.黄惠华,梁汉华.2006.利用微波辅助萃取技术提取五味子果实中五味子醇甲的研究[J].天然产物研究于开发,(18)：112-116.
28.黄玲,张捷平,陈华.2003.五味子多糖对S180荷瘤小鼠抑瘤作用的研究[J].福建中医学院学报,13(3)：22-24
29.黄少伟,池汝安,张越非,等.2007.土茯苓多糖提取的最优化工艺[J].时珍国医国药,(11).
30.黄天辉,沈平攘.2006.均质设计优选微波萃取五味子的工艺研究[J].中成药,28(8)：1111-1113.
31.黄秀榕,祁明信,江朝阳,等.2002.五味子乙素对氧化损伤的晶状体上皮细胞凋亡影响[J].中国病理生理杂志,18(12)：1502.
32.黄秀榕,祁明信,叶蕻芝,等.2001.五味子乙素防护晶状体氧化损伤的体外实验研究[J].中国药学杂志36(5)：310.
33.霍艳双,陈晓辉,李康.2005.北五味子的镇静、催眠作用[J].沈阳药科大学报,22(2)：126-128.
34.金岳雷,范晓艳,吕冬霞,张玉萍.2008.五味子乙素对H-22荷瘤小鼠抑制作用的病理学研究[J].31(5)：7-8
35.康文艺,臧鑫炎,李黎.2006.茜草抗氧化成分研究[J].河南大学学报,25(32)：6.
36.李爱民,艾军,王玉兰,等.2001.北五味子规范化栽培与加工技术[M].北京：中国劳动社会保障出版社.
37.李八方.1997.功能食品与保健食品[M].青岛：青岛海洋大学出版社：96.
38.李海涛,胡刚.2004.五味子醇甲抑制62轻基多巴胺诱导PC12细胞凋亡的研究[J].南京中医药大学学报,20(2)：96-99.
39.李娟,张耀庭,曾伟.2000.应用考马斯亮蓝法测定总蛋白含量.中国生物制品学杂志,13(1)：118-120.
40.李莉.1997.五味子酚对氧自由基损伤小鼠脾淋巴细胞的保护作用[J].药学学报,32(3)：178-182.
41.李莉.1997.五味子酚对氧自由基损伤小鼠脾淋巴细胞的保护作用.药学学报,32(3)：178-182.
42.李巧如,刘宗智,任健康,等.2001.丁香提取物抗菌机理的探讨[J].西北药学杂志,16(6)：261-262.
43.李霞,贾晓斌,陈彦等.2007.五味子提取工艺的优化研究.中国药房,8(6)：424-426.
44.李晓光,高勤,翁公,等.2005.五味子有效部位及其药理作用研究进展[J].中药材,28(2)：156-159.
45.李晓光.2005.五味子有效部位及其药理作用研究进展[J].中药材,28(2)：156-159.
46.李晓宁,崔卉,宋又群,等.2001.辽五味子果实挥发油成分的鉴定[J].药学学报,36(3)：215-219.
47.梁文斌,谢碧霞,邓白罗.2006.五味子属药用植物木脂素的研究现状与展望[J].经济林研究,24(4)：77-82.
48.梁文斌,谢碧霞,邓白罗.2006.五味子属药用植物木脂素的研究现状与展望.经济林研究,24(4)：77-82.
49.廖工铁,晏玉英,杨华元.1979.生脉注射液制备工艺的研究[J].中草药通讯,12(9)：17-20.
50.刘本,Dean, J R, Price R,等.2000.法多索溶剂提取五味子中的五味子甲素[J].中药,22(7)：507-509.
51.刘本,John R Dean.1989超临界C02流体提取五味子中的五味子甲素[J].中国医药工业杂志,(231)：101-103.
52.刘长姣,张守勤,吴华,2006.超高压技术在五味子饮料加工中的应用[J]..农业工程学报,22(6)：227.
53.刘琥琥,罗集鹏,赖沛炼.1999.广东高要与吴川产广藿香提取物对肠道致病菌抗菌作用的比较研究[J].中药材,22(8)：408-411.
54.刘继永,王英平,刘洪章,等.2005.五味子化学成分及药理研究进展[J].特产研究,(3)：49-54.
55.刘力生,肖显华,王肖萱,等.1984.γ-五味子素对癌细胞DNA、ATP和核蛋白代谢的影响[J].中国药理学报,5(2)：130.
56.刘琼辉,廖满琴.2006.五味子甲素存在部位的探索及意义.成都中医药大学报,29(1)：62.
57.刘泽敏,黄玉明.2006.流动注射化学发光法测定芹菜素[J].西南师大学报,3：27.
58.柳艳,李磊,赵鸿雁.2006.丹酚酸B清除DPPH有机自由基活性及影响因素研究[J].时珍国医国药,17(12)：2406.
59.芦金清,何则华,张宝军,等.1998.五味子提取工艺的研究[J].中成药,20(12)：1-2.
60.孟广森,周永刚,张玉华.2003.HPLC法测定养肝胶囊中五味子醇甲的含量[J].中国新医药,(4)：30-31.
61.慕芳英,金美花,刘仁俊.2005.五味子果实、藤茎及果柄的成分分析[J].延边大学医学学报,28(1)：29-31.
62.聂江力,裴毅,祖元刚.2005.北五味子果实超临界CO2萃取工艺的研究[J].植物研究,25(2)：213-215.
63.庞浩龙,李站立,贡联兵.2004.正交试验法确定五味子的提取工艺[J].中华临床医药,5(12)：111-112.
64.沈宁,敬晓丽,陈晓春,等.2006.南五味子中五味子甲素的薄层扫描色谱定量分析[J].化学研究与应用,18(6)：741-743.
65.宋华湘.2004.中药五味子中木脂素类成分的HPLC-MS研究及以中草药生物活性成分为基础的主成分聚类分析[D].湖南师范大学,40-46.
66.宋小妹,考玉萍.2004.不同产区南五味子中木脂素含量测定[J].陕西中医,25(7)：645-646.
67.孙成仁,彭正松.1993.北五味子的抑菌作用[J].四川师范学院学报：自然科学版,14(3)：200-202.
68.孙汗董,李蓉涛,肖伟烈.2005.五味子属植物新骨架降三萜类化合物及其生物活性研究[A].中国化学会第四届有机化学学术会议[C].331-322.
69.谭晓梅,陈飞龙.2002.超临界COz萃取法与水蒸气蒸馏法提取的北五味子挥发油成分分析[J].中药材,25(11)：796-797.
70.汪有初,周俊,谭宁华,等.1999.五味子的环二肽及其合成[J].药学学报,34(1)：19-22.
71.王艳,张铁军.2005.微波萃取技术在中药有效成分提取中的应用[J].中草药,36(3)：470-473.
72.王茹,张琰等.2005.五味子活性成分提取工艺的优选,华南国防医学杂志,2005,19(6)：4-6.
73.王森,张建国.2003.五味子的研究概况及其开发前景[J].经济林研究,21(4)：126-127.
74.工少敏,李萍,赵明强.2003.生物化学发光法测定酸枣仁的抗氧化活性[J].中草药,34(5)：417.
75.王卫峰,金惠敏,丁腈,等.1999.比色法测定南五味子中总木脂素的含量[J].西北药学杂志,14(5)：197.
76王炎,王进福,尤宏,等.2001.北五味子种子挥发油的GC-MS分析[J].中国药学杂志,36(2)：91-92.
77.王彦涵,高建平,陈道峰,等.2003.高效液相色谱法测定五味子属药用植物木脂素的含量[J].中国中药杂志,28(12)：1155-1159.
78.王彦涵,高建平,郁韵秋,等.2003.HPLC法测定红花五味子木脂素的含量[J].中草药,34(10)：951-953.
79.王英范,郜玉刚,刘雅婧,等.2006.五味子乙素抗梅花鹿源BVDV的实验研究[J].特产研究,(2)：5-8.
80.王振雨,孙芳,刘荣.2006.微波辅助提取松仁多糖的研究[J].食品工业科技,27(9)：133-135.
81.吴青,黄娟,罗兰欣,等.2006.15种中草药提取物抗氧化活性的研究[J].中国食品学报,6(1)：284.
82.吴拥军,石杰,屈凌波,等.2006.流动注射化学发光法及光度法用于巴戟天提取液抗氧化活性的研究[J].光谱学与光谱分析,26(9)：1688.
83.夏晓凯,张庭廷,陈传平.2006.黄精多糖的体外抗氧化作用研究[J].湖南中医杂志,22(4)：90.
84.向智敏,李会林,张骊.2003.五味子超临界CO2提取物的气相色谱-质谱分析[J],色谱,21(6)：568-571.
85.徐海波,郑友兰,张崇禧.2005.气相层相-质谱分析法分析北五味子藤茎挥发油成分[J].成都中医药报,28(1)：60-62.
86.徐林峰,沈忠明,殷建伟,等.2001.五味子中提取α-葡葡糖苷酶抑制剂的研究[J].中国生化药物杂志,22(3)：127-128.
87.薛梅,周静,王鲁石,等.2003.五味子多糖的提取及含量测定[J].陕西中医,24(3)：267-268.
88.严梅桢,高晓山,刘林详,等.1998.黄连与黄芩、甘草配伍前后对金黄色葡萄球菌生长抑制作用的观察[J].中国中药杂志,23(6)：375-378.
89.杨放,袁军,付平.2003.五味子的研究概况[J].华西药学杂志,18(6)：438-440.
90.杨苏蓓.2001.超临界流体萃取五味子中木脂素等成分的工艺研究[J].中国中药杂志,26(11)：755-757.
91.仰榴青,吴向阳,徐佐旗,等.2005.五味子及其制剂中木脂素类成分含量测定的研究进展[J].中国中药杂志,30(9)：650-653.
92.尹湉,刘严生,于叶玲,唐星.2007.用大孔树脂提取和纯化五味子总木脂素[J].沈阳药科大学学报,24(2)：113-117.
93.应国清,俞志明,单剑峰,等.2005.北五味子有效组分的研究进展[J].河南中医,25(6)：84-87.
94.于俊林,李世慧,陈晶,等.1998.北五味子根、茎、叶与果实木脂素成分比较研究[J].人参研究,(1)：11-12.
95.于俊林,秦瑀,胡彦武,等.2003.HPLC法测定五味子茎藤中木脂素的含量[J].中草药,34(10)：9-10.
96.岳文.2002.中药库中的十大抗氧化剂,癌症康复,(2)：22-23.
97.张兰杰,张维华,赵珊红.2002.北五味子果实中多糖的提取与纯化研究[J].鞍山师范学院学报,4(1)：58-60.
98. Altmann KH, Gertsch J.2007.Anticancer drugs from nature-natural products as a unique source of new microtubule-stabilizing agents[J].Nat Prod Rep,24(2):327.
99. Batist G, Barton J, Chaikin P.2002. My ocet(liposome encapsulated doxorubicin citrate):A new approach in breast cancer therapy [J]. Expert Opin Pharmacother,3(12):1739-1751.
100. Benzie IF,Strain JJ.1996.The ferric reducing ability of plasma (FRAP) as a measure of antioxidant power:the FRAP assay[J].AnalBiochem,(239):70.
101. Benzie IF,Strain JJ.1996.The ferrric reducing ability of plasma (FRAP) as a measure of antioxidant power the FRAP assay[J].Anal Biochem,(239):70.
102. Brisaert M, Gabriels M,Matthijs Vet al.2001.Liposomes tretinoin: a physical chemical evaluation [J] Pharm.Biomed.Ana.,26:909-917
103. Bryant AE 3rd,Dreifuss FE.1996.Valproic acid hepatic fatal it ies, IILU.S.experience since 1986[J].Neurology,46(2):465-469.
104. Chen AJ, Li CH, Gan WH et al.2005. Separation and determination of active components in schisandra chinensis Baill. And its medicinalpreparations by non-aqueous capillary electrophoresis.Biomedical Chromatography,19(7):481-487.
105. Chen Y G, Qin G W, Xie Y Y.2001. Lignans frome plants of schisandraceae. Chem. World, 2001(7):380-383.
106. Chiu,P.Y,Mak,D.H.F.,Poon,M.K.T.,Ko,K.M.2002.In vivo antioxidant action of alignan-enriched extract of Schisandra fruit and an anthraquinone-containing extract of Polygonum root in comparison with y-schizandrin and emodin.Planta Medics,(English),68(11):951-956.
107. Chiu,P.Y,Mak,D.H.F.,Poon,M.K.T.,Ko,K.M.2002.In vivo antioxidant action of alignan-enriched extract of Schisandra fruit and an anthraquinone-containing extract of Polygonum root in comparison with y-schizandrin and emodin.Planta Medics, (English),68(11):951-956.
108. Chiu,P.Y,Mak,D.H.F.,Poon,M.K.T.,Ko,K.M.2002.In vivo antioxidant action of alignan-enriched extract of Schisandra fruit and an anthraquinone-containing extract of Polygonum root in comparison with y-schizandrin and emodin.Planta Medics,(English),68(11):951-956.
109. CODERCH L,FONOLLOS J,DF PERA M,et al.2000.Influence of cholesterol on liposome fluidity by EPR relationshio with percutaneous absorption [J].J of Controllde Release,68:85-95.
110. Crino PB,Hong J,Melissa D.Shumate,et a 1.2002.Increased axpression of the neuronal glutamate transpoeter(EE-AT3/EAACl)in hippocampal neocortical epilepsy[J].Epilepsia,43(3):211-218.
111. Dreifuss FE,Santilli N, Langer DH, et al.1987.Valproic acid hepatic fatalities:a retrospective review [J].Neurology,37(3):379-385.
112. Elbayoumi TA,Torchilin VP.2007.Enhanced cytotoxicity of monoclonal anticancer antibody modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines[J].Eur J Pharm Sci, 32(3):159.
113. FOGLI S, NIERI P, BRESCHI M C.2004.The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage[J].FasebJ,18(6):664-75.
114. Ganzler K.1990.Microwave extraction anoval sample preparation method for chromalography[J]. Journal of Chromalography,257-262.
115. Ganzler K.1990.Microwave extraction anoval sample preparation method for chromalography[J].Journal of Chromalography,257-262.
116. Gottlieb H E, Mervic M, Ghera E J.1982. Chem Soc Perkin Trans,1982(10):2353-2358.
117. Graziadei I W,Obermoser G E,Sepp N T,et al.2003.Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis[J].Lupus,12(5):409-412.
118. Grillo MP,Chiellini G.Tonelli M, et al.2001.Effect of alpha-fluorination of valp roicacid on valp royl-Sacyl-Co A formation in vivoin rats [J].Drug Metab Dispos,29 (9):1210-1215.
119. Hana trova, Petra evikova,Leona Kvasnikova, et al.2002.Detemination of lignans in Schisandra chinensis using micellar electrokinetic capillary chromatography[J]. Electr-ophoresis,23(2):253-258.
120. Hana trova,Petra evikova,Leona Kvasnikova,et al.2002.Detemination of lignans in Schisandra chinensis using micellar electrokinetic capillary chromatography[J].Electrophoresis,23(2):253-258.
121.Hana trova,Petra evikova,Leona Kvasnikova,et al.2002.Detemination of lignans in Schisandra chinensis using micellar electrokinetic capillary chromatography[J].Electrophoresis,23(2):253-258.
122. Hancke, J.L, Burgos, R.A, Ahumada, F.1999. Schisandra chinensis(Trucz.) Baill. Fitogetherapia, 70:451-471.
123. Hartmut Jaeschke, Gregory J, Gores, et al.2002.Machanisms of Hepatotoxicity[J].Toxicological Sciences,65 (2):166-176.
124. Hiroichi N, Ikuhisa Y, Motonofi A.1989. The Effect of Gomisin A on Immumlogic Liver Injury in Mice. Planta Meedic,55(1):13.
125. Huang TH,Shen PN,Shen YJ.2005.Preparative separation and purification of deoxyschisandrin and y-schisandrin from schisandra chinensis(Turcz.)Baill by high-speed counter-current chromatography[J].Journal of Chromatography A,1066(1/2):239-242.
126. Huang TH,Shen PN,Shen YJ.2005.Preparative separation and purification of deoxyschisandrin and aγ-schisandrin from schisandra chinensis(Turcz.)Baill by high-speed counter-current chromatography [J].Journal of Chromatography A,1066(1/2):239-242.
127. HuangTH,Shen PN, Shen YJ.2005.Preparative separation and purification of deoxyschisandrin and ay-schisandrin from schisandra chinensis(Turcz.)Baill by high-speed counter-current chromatography [J] Journal of Chromatography A,1066(1/2):239-242.
128. IP S P,POON M K,CHE C T,et al.1996. Γ-schizandrin protects against carbon tetrachloride toxicity by enhancing the mitochondrial glutathione redox status inmouse liver[J]. Free Radic Biol Med,2 1(5):709-712.
129. Jain KK.2000.An assessment of ralinamide as an anti-epileptic in comparison with other drugs in clinical development[J].Expert Opin Invetig Drugs,9:829-840.
130. Kadsulignan N, LIU Jin-sen, Li Liang.1995. three dibenzocy-clooctadiene lignans from kadsura coccinea. Phytochemistry,38(1):241.
131. KangDeogSung.2000.FSTA,31(8):30.
132. Kim HC,Ko KH,Kim WK,etal.2001.Effects of dextromethorphan on the seizure induced by kainite and the calcium channel agonist Bayk-8644:comparison with the effects of dextrorphan[J]. Behav brain Res,120(2):169-175.
133. Ko K M,Lam B Y H,Ko K M,Mol.2002.Cell. Boichem,238(1):181-186.
134. Ko K M,Lam B Y H,Ko K M,Mol.2002.Cell. Boichem,238(1):181-86.
135. KO K M,YIU H Y.2001. Γ-schizandrin modulates the ischemia-reperfusion induced changes in non-enzymatic antioxidant levels in isolated-perfused rat hearts[J]. Mol Cell Biochem,220 (1-2):141-147.
136. Krahenbuhl S,Mang G,Kupferschmidt H,et al.1995.Plasma and hepatic carnitine and coenzyme A pools in a patient with fatal, valproate induced hepatotoxicity[J].Gut,37(1):140-143.
137. Kuo Y H, Li SY, WuM Det al.1999. Chem. Pharm.. Bull,47(7):1047-1408.
138. Lei Zhang,Hong Pan,Min Liu.2004.In vitro and in vivo stabilities of doxorubicin aggregates with various salts insideliposomes.Acta Pharmaceutica Sinica 39(12):1018-1022
139. Li L, Lu Q, Shen Y, et al.2006.Γ-schizandrin enhances doxorubicin-induced apoptosis of cancer cells but not normal cells [J]. Biochem Pharmacol, (71):584-595.
140. Meng Sun1,Xiaoli Xu1,Qinghua Lu,Qiangrong Pan,Xun Hu,2007. Γ-schizandrin:A dual inhibitor of P-glycoprotein and multidrug resistance-associated protein 1,Cancer Letters,246:300-307
141. Meng Sun1,Xiaoli Xu1,Qinghua Lu,Qiangrong Pan,Xun Hu,2007. Γ-schizandrin:A dual inhibitor of P-glycoprotein and multidrug resistance-associated protein 1,Cancer Letters,246:300-307.
142.MINOTTI G MENNA P, SALVATORELLI E, et al.1999.Anthracyclines: molecular Modified,itll an enbancer containing insulin in rabbits[J].DrugDev.Int.Pharm.25 (10):1099-1105
143. Muramatsu K, Maitani Y,Takayama K, et al.1999.The relationship between the rigidity of the Liposomeal membrane and the absorption of in insulin after nasal administration of liposom- es modified,itll an enbancer containing insulin in rabbits[J]. Drug Dev.Int.Pharm,25(10):1099-1105.
144. MURAOKA S,MIURA T.2003.Free radicals mediate cardiac toxicity induced byadriamycin[J]. Yakugaku Zasshi,123(10):855-66.
145. Nelson RM,green AR,lambert DG,et al.2000.On the regulation of ischaemia-induced glutamte efflux from rat codex by GABA,in vitro studies with GABA,clomethiazole and pentobarbitone[J].Br J Pharmacol,130(5):1124-1130.
146. Pare J R J,Sigouin M.1991.Microwave-assisted natural products extraction.U.S.Patent,No.5002784.
147. Patel T,Bronk S.F, Gores G,J.1994.Increases of intracellular magnesium promote glycodeoxycholate-induced apoptosis in rat hepatocytes[J].J.Clin.Invest,40 (1):2183-2192.
148. Patel V B,Misra A N.1999.Encapsulation and stability of clofazimine liposomes[J].16:357-367
149. Peng JY,Fan GR, Qu LP,et al.2005.Application of preparative high-speed counter chromatography for isolation and separation of schizandrin and gomisin A from Schisandra chinensis[J].Journal of Chromatography A,1082(2):203-207.
150. Peng JY,Fan GR,Qu LP,et al.2005.Application of preparative high-speed counter chromatography for isolation and separation of schizandrin and gomisin A from Schisandra chinensis[J]. Journal of Chromatography A,1082(2):203-207.
151. Peng JY,Fan GR,Qu LP,et al.2005.Application of preparative high-speed counter chromatography for isolation and separation of schizandrin and gomisin A from Schisandra chinensis[J]. Journal of Chromatography A,1082(2):203-207.
152. PENG X,CHEN B,LIM C C,et al.2005.The cardiotoxicology of anthracycl inechemotherapeutics: translating molecular mechanism into preventative medicine[J].MolInterv,5(3):163-171.
153. Perucca E.2002.Pharmacological and therapeutic properties of valproate:a summary after 35 years of clinical experience[J].CNS Drugs,16(10):695-714.
154. Peter JE,Eduard P,Krenzelok.1999.Treatment of acetaminophen overdose[J].Am J Healdl-syst,56 (11):1081-1091.
155.Po Yee Chiu, Duncan H.F. Mak, Michel K.T. Poon, Kam Ming Ko.2005. Role of cytochrome P-450 in γ-schizandrin-induced antioxidant and heat shock responses in mouse liver. Life Sciences,77 (2005):2887-2895.
156. Po Yee Chiu,Duncan H.F. Mak,Michel K.T.Poon,Kam Ming Ko.2005.Role of cytochrome P-450in γ-schizandrin-induced antioxidant and heat shock responses in mouse liver,Life Sciences,77: 2887-2895.
157. Po Yee Chiu,Duncan H.F. Mak,Michel K.T.Poon,Kam Ming Ko.2005.Role of cytochrome P-450in γ-schizandrin-induced antioxidant and heat shock responses in mouse liver,Life Sciences,77:2887-2895.
158. Poivier V J, Thamm D H, Kurzman I D, et al.2002. Liposome encapsulated doxorubicin(doxil) and doxorubicin in the treatment of vaccine associated sarcoma in rat [J]. J. Vet. Intern. Med.,16(6): 726-731.
159. Schwarzinger C,Kranawetter H.2004.Analysis of the active compounds in different parts of the schisandra chinensis plant by means of pyrolysis-GC/MS[J].Monatshefte fur Chemie Chemical Monthly,(135):1201-1208.
160. Schwarzinger C,Kranawetter H.2004.Analysis of the active compounds in different parts of the schisandra chinensis plant by means of pyrolysis-GC/MS[J].Monatshefte fur Chemie Chemical Monthly,(135):1201-1208.
161. Su J D et al.1998.Phytochemisery,27:1315-1320.
162. SUKOWSKIA W W,PENTAK D,NOWAK K,et al.2005.The influence of temperature,cholesterol content and pH on liposome stability [J]. Journal of Molecular Structure,744-747:737-747.
163. Tian K,Qi SD,Chen YQ,et al.2005.Separation and determination of lignans from seeds of schisandra species by micellar electrokinetic capillary chromatography using ionic liquid as modifier [J].Chromatography A,1078(1/2):181-187.
164. Tian K,Qi SD,Chen YQ,et al.2005.Separation and determination of lignans from seeds of schisandra species by micellar electrokinetic capillary chromatography using ionic liquid as modifier[J].Chromatography A,1078(1/2):181-187.
165.Tober C.Rostoek A,Rundfeldt C.1996.D-23129:A potent anticonvul sant in the amygdale kindling model of complex partial seizures[J].Eur J Pharmacol,303:163-169.
166. VARVARESOU A,IAKOVOU K,GIKAS E,et al.1996.Antitumor activity of vesicle method [J].Chem:Pham.Bull.44(1):237-240
167. William M,Lee,M.D.1995.Drug-induced hepatotoxicity The New Eng[J].Journal of Medicine,333 (17): 1118-1125.
168. WOUTERS K A, KREMER L C,MILLER T L,et al.2005.Protecting against anthracycline induced myocardial damage:a review of the most promisingstrategies[J].Br J Haematol,131 (5):561-578.
169. Wu YF,Cao MF,.Gao YP,et al.2004.Down-modulation of heat shock protein 70 and up-modulantion of Caspase-3 during y-schizandrin-induced apoptosis in human hepatoma SMMC-7721 cells.Word J Gastroentrerol.(10):2944-2948
170. YIM T K KO K M.1999. Γ-schizandrin protects against myocardial ischemia-reperfusion injury by enhancing myocardial glutathione antioxidantstatus[J]. Mol CellBiochem,196 (1-2):151-156.
171. Zakim D,Thomas D.1996.Hepatology[M].Third edition,USA:WB Sanders Comtpany,962-967.
172. Zhang Shouqin, Zhu Junjie,Wang Changzhen.2004.Novel high pressure extraction technology [J].International Journal of Pharmaceutics,27(8):471.
173. Zhang Tiemei,Wang Banen,Liu Gengtao.1992.Effect of γ-schizandrin onlipoperoxidative damage to plasma memebrane of rat liver in vitro [J].Acta Pharmacologica Sinica,13(3):255-258.
2.常向明,刘小平,姚垂宇,等.1995.香连丸联用TMP抗菌作用的实验研究[J].中国药房,6(4)：16-17.
3.常向明,姚垂宇,刘小平,等.1994.黄连联用TMP抗菌作用的实验研究[J].中国中药杂志,19(12)：748-750.
4.陈斯泽,汪森明,张积仁.2008.盐酸洛拉曲克长循环脂质体制备及其抑瘤特性研究[J].南方医科大学学报,3：403-405
5.陈业高,秦国伟,谢毓元.2001.五味子科植物木脂素成分的化学[J].化学世界,(7)：44-47.
6.程国强,冯年平,唐琦文,等.2001.黄芩苷对眼科常见病原菌的体外抗菌作用[J].中国医院药学杂志,21(6)：347-348.
7.戴好富,周俊,彭再刚,等.2000.北五味子的水溶性化学成分[J].天然产物研究与开发,13(1)：24-26.
8.邓胜国,邓泽元,黄丽.2006.荷叶黄酮体外抗氧化活性的研究[J].食品科技,7：274.
9.邓英杰,史淑芬,顾学裘.1988.油酸多相脂质体注射液包封率测定方法的研究[J].药学学报,23(7)：534-544.
10.丁劲松,杨敏,陈琼.2004.聚乙二醇衍生化磷脂与脂质体立体稳定性[J].中国医药工业杂志,35(1)：55-58.
11.范健,文旭,缪玉山.2001.脂质体阿霉素与游离阿霉素在大鼠体内药代动力学中国药科大学学报,32(5)：354-358
12.付绍平,张峰,张慧,等.2004.反相高效液相色谱法测定五味子中木脂素的含量[J].现代中药研究与实践,(18)：32-34.
13.高建平,王彦涵,郁韵秋,等.2003.南五味子木脂素成分的HPLC含量测定及其变异规律[J].中国天然药物,1(2)：89-93.
14.高普军,朴云峰,郭晓琳.1995.北五味子粗多糖保肝作用的机理[J].白求恩医科大学学报,21(2)：147-148.
15.高普军,朴云峰,郭晓琳.1995.北五味子粗多糖保肝作用的机理[J].白求恩医科大学学报,21(2)：147-148.
16.高荣海等.2006.大孔吸附树脂对大豆异黄酮吸附性能的研究,研究与探讨[J],27(10)：49-51.
17.高思海,潘铁成,李平.2004.五味子酚对大鼠心脏移植供心的保护作用研究[J].中华实用中西医杂 志,4(17)：1-3.
18.高晔珩,宋小妹,冯改利.2005.不同产地南五味子质量分析研究[J].陕西中医,26(8)：836-837.
19.关洪全,李海波,李建春,等.2000.生姜与乳酸协同对食品防腐作用的基础研究[J].中国中医药信息杂志,7(2)：27-28.
20.郭春梅.2003.不同产地的五味子中五味子乙素含量测定[J].黑龙江医药,16(1)：6-7.
21.韩学君,王发善.2003.北五味子有效成分的高效液相层析测定[J].黑龙江医药科学,26(4)：104.
22.韩止洲,李亚凤.1997.南、北五味子的薄层色谱鉴别及定量分析[J].时珍国药研究,8(4)：334-335.
23.郝金玉.2001.微波萃取除虫菊酯[J].精细石油化工,(2)：47-49.
24.郝书文,宋桂娥.2003.北五味子果梗的药用研究[J].山东医药工业,22(2)：8-9.
25.何来英,冯晓莲,孙明,等.2004.五味子的急性毒性和遗传毒性研究[J].1 1(4)：645-648.
26.胡博路,孟洁,胡迎芬.2000.30种中草药清除自由基的研究[J].青岛大学学报,13(2)：38.
27.黄惠华,梁汉华.2006.利用微波辅助萃取技术提取五味子果实中五味子醇甲的研究[J].天然产物研究于开发,(18)：112-116.
28.黄玲,张捷平,陈华.2003.五味子多糖对S180荷瘤小鼠抑瘤作用的研究[J].福建中医学院学报,13(3)：22-24
29.黄少伟,池汝安,张越非,等.2007.土茯苓多糖提取的最优化工艺[J].时珍国医国药,(11).
30.黄天辉,沈平攘.2006.均质设计优选微波萃取五味子的工艺研究[J].中成药,28(8)：1111-1113.
31.黄秀榕,祁明信,江朝阳,等.2002.五味子乙素对氧化损伤的晶状体上皮细胞凋亡影响[J].中国病理生理杂志,18(12)：1502.
32.黄秀榕,祁明信,叶蕻芝,等.2001.五味子乙素防护晶状体氧化损伤的体外实验研究[J].中国药学杂志36(5)：310.
33.霍艳双,陈晓辉,李康.2005.北五味子的镇静、催眠作用[J].沈阳药科大学报,22(2)：126-128.
34.金岳雷,范晓艳,吕冬霞,张玉萍.2008.五味子乙素对H-22荷瘤小鼠抑制作用的病理学研究[J].31(5)：7-8
35.康文艺,臧鑫炎,李黎.2006.茜草抗氧化成分研究[J].河南大学学报,25(32)：6.
36.李爱民,艾军,王玉兰,等.2001.北五味子规范化栽培与加工技术[M].北京：中国劳动社会保障出版社.
37.李八方.1997.功能食品与保健食品[M].青岛：青岛海洋大学出版社：96.
38.李海涛,胡刚.2004.五味子醇甲抑制62轻基多巴胺诱导PC12细胞凋亡的研究[J].南京中医药大学学报,20(2)：96-99.
39.李娟,张耀庭,曾伟.2000.应用考马斯亮蓝法测定总蛋白含量.中国生物制品学杂志,13(1)：118-120.
40.李莉.1997.五味子酚对氧自由基损伤小鼠脾淋巴细胞的保护作用[J].药学学报,32(3)：178-182.
41.李莉.1997.五味子酚对氧自由基损伤小鼠脾淋巴细胞的保护作用.药学学报,32(3)：178-182.
42.李巧如,刘宗智,任健康,等.2001.丁香提取物抗菌机理的探讨[J].西北药学杂志,16(6)：261-262.
43.李霞,贾晓斌,陈彦等.2007.五味子提取工艺的优化研究.中国药房,8(6)：424-426.
44.李晓光,高勤,翁公,等.2005.五味子有效部位及其药理作用研究进展[J].中药材,28(2)：156-159.
45.李晓光.2005.五味子有效部位及其药理作用研究进展[J].中药材,28(2)：156-159.
46.李晓宁,崔卉,宋又群,等.2001.辽五味子果实挥发油成分的鉴定[J].药学学报,36(3)：215-219.
47.梁文斌,谢碧霞,邓白罗.2006.五味子属药用植物木脂素的研究现状与展望[J].经济林研究,24(4)：77-82.
48.梁文斌,谢碧霞,邓白罗.2006.五味子属药用植物木脂素的研究现状与展望.经济林研究,24(4)：77-82.
49.廖工铁,晏玉英,杨华元.1979.生脉注射液制备工艺的研究[J].中草药通讯,12(9)：17-20.
50.刘本,Dean, J R, Price R,等.2000.法多索溶剂提取五味子中的五味子甲素[J].中药,22(7)：507-509.
51.刘本,John R Dean.1989超临界C02流体提取五味子中的五味子甲素[J].中国医药工业杂志,(231)：101-103.
52.刘长姣,张守勤,吴华,2006.超高压技术在五味子饮料加工中的应用[J]..农业工程学报,22(6)：227.
53.刘琥琥,罗集鹏,赖沛炼.1999.广东高要与吴川产广藿香提取物对肠道致病菌抗菌作用的比较研究[J].中药材,22(8)：408-411.
54.刘继永,王英平,刘洪章,等.2005.五味子化学成分及药理研究进展[J].特产研究,(3)：49-54.
55.刘力生,肖显华,王肖萱,等.1984.γ-五味子素对癌细胞DNA、ATP和核蛋白代谢的影响[J].中国药理学报,5(2)：130.
56.刘琼辉,廖满琴.2006.五味子甲素存在部位的探索及意义.成都中医药大学报,29(1)：62.
57.刘泽敏,黄玉明.2006.流动注射化学发光法测定芹菜素[J].西南师大学报,3：27.
58.柳艳,李磊,赵鸿雁.2006.丹酚酸B清除DPPH有机自由基活性及影响因素研究[J].时珍国医国药,17(12)：2406.
59.芦金清,何则华,张宝军,等.1998.五味子提取工艺的研究[J].中成药,20(12)：1-2.
60.孟广森,周永刚,张玉华.2003.HPLC法测定养肝胶囊中五味子醇甲的含量[J].中国新医药,(4)：30-31.
61.慕芳英,金美花,刘仁俊.2005.五味子果实、藤茎及果柄的成分分析[J].延边大学医学学报,28(1)：29-31.
62.聂江力,裴毅,祖元刚.2005.北五味子果实超临界CO2萃取工艺的研究[J].植物研究,25(2)：213-215.
63.庞浩龙,李站立,贡联兵.2004.正交试验法确定五味子的提取工艺[J].中华临床医药,5(12)：111-112.
64.沈宁,敬晓丽,陈晓春,等.2006.南五味子中五味子甲素的薄层扫描色谱定量分析[J].化学研究与应用,18(6)：741-743.
65.宋华湘.2004.中药五味子中木脂素类成分的HPLC-MS研究及以中草药生物活性成分为基础的主成分聚类分析[D].湖南师范大学,40-46.
66.宋小妹,考玉萍.2004.不同产区南五味子中木脂素含量测定[J].陕西中医,25(7)：645-646.
67.孙成仁,彭正松.1993.北五味子的抑菌作用[J].四川师范学院学报：自然科学版,14(3)：200-202.
68.孙汗董,李蓉涛,肖伟烈.2005.五味子属植物新骨架降三萜类化合物及其生物活性研究[A].中国化学会第四届有机化学学术会议[C].331-322.
69.谭晓梅,陈飞龙.2002.超临界COz萃取法与水蒸气蒸馏法提取的北五味子挥发油成分分析[J].中药材,25(11)：796-797.
70.汪有初,周俊,谭宁华,等.1999.五味子的环二肽及其合成[J].药学学报,34(1)：19-22.
71.王艳,张铁军.2005.微波萃取技术在中药有效成分提取中的应用[J].中草药,36(3)：470-473.
72.王茹,张琰等.2005.五味子活性成分提取工艺的优选,华南国防医学杂志,2005,19(6)：4-6.
73.王森,张建国.2003.五味子的研究概况及其开发前景[J].经济林研究,21(4)：126-127.
74.工少敏,李萍,赵明强.2003.生物化学发光法测定酸枣仁的抗氧化活性[J].中草药,34(5)：417.
75.王卫峰,金惠敏,丁腈,等.1999.比色法测定南五味子中总木脂素的含量[J].西北药学杂志,14(5)：197.
76王炎,王进福,尤宏,等.2001.北五味子种子挥发油的GC-MS分析[J].中国药学杂志,36(2)：91-92.
77.王彦涵,高建平,陈道峰,等.2003.高效液相色谱法测定五味子属药用植物木脂素的含量[J].中国中药杂志,28(12)：1155-1159.
78.王彦涵,高建平,郁韵秋,等.2003.HPLC法测定红花五味子木脂素的含量[J].中草药,34(10)：951-953.
79.王英范,郜玉刚,刘雅婧,等.2006.五味子乙素抗梅花鹿源BVDV的实验研究[J].特产研究,(2)：5-8.
80.王振雨,孙芳,刘荣.2006.微波辅助提取松仁多糖的研究[J].食品工业科技,27(9)：133-135.
81.吴青,黄娟,罗兰欣,等.2006.15种中草药提取物抗氧化活性的研究[J].中国食品学报,6(1)：284.
82.吴拥军,石杰,屈凌波,等.2006.流动注射化学发光法及光度法用于巴戟天提取液抗氧化活性的研究[J].光谱学与光谱分析,26(9)：1688.
83.夏晓凯,张庭廷,陈传平.2006.黄精多糖的体外抗氧化作用研究[J].湖南中医杂志,22(4)：90.
84.向智敏,李会林,张骊.2003.五味子超临界CO2提取物的气相色谱-质谱分析[J],色谱,21(6)：568-571.
85.徐海波,郑友兰,张崇禧.2005.气相层相-质谱分析法分析北五味子藤茎挥发油成分[J].成都中医药报,28(1)：60-62.
86.徐林峰,沈忠明,殷建伟,等.2001.五味子中提取α-葡葡糖苷酶抑制剂的研究[J].中国生化药物杂志,22(3)：127-128.
87.薛梅,周静,王鲁石,等.2003.五味子多糖的提取及含量测定[J].陕西中医,24(3)：267-268.
88.严梅桢,高晓山,刘林详,等.1998.黄连与黄芩、甘草配伍前后对金黄色葡萄球菌生长抑制作用的观察[J].中国中药杂志,23(6)：375-378.
89.杨放,袁军,付平.2003.五味子的研究概况[J].华西药学杂志,18(6)：438-440.
90.杨苏蓓.2001.超临界流体萃取五味子中木脂素等成分的工艺研究[J].中国中药杂志,26(11)：755-757.
91.仰榴青,吴向阳,徐佐旗,等.2005.五味子及其制剂中木脂素类成分含量测定的研究进展[J].中国中药杂志,30(9)：650-653.
92.尹湉,刘严生,于叶玲,唐星.2007.用大孔树脂提取和纯化五味子总木脂素[J].沈阳药科大学学报,24(2)：113-117.
93.应国清,俞志明,单剑峰,等.2005.北五味子有效组分的研究进展[J].河南中医,25(6)：84-87.
94.于俊林,李世慧,陈晶,等.1998.北五味子根、茎、叶与果实木脂素成分比较研究[J].人参研究,(1)：11-12.
95.于俊林,秦瑀,胡彦武,等.2003.HPLC法测定五味子茎藤中木脂素的含量[J].中草药,34(10)：9-10.
96.岳文.2002.中药库中的十大抗氧化剂,癌症康复,(2)：22-23.
97.张兰杰,张维华,赵珊红.2002.北五味子果实中多糖的提取与纯化研究[J].鞍山师范学院学报,4(1)：58-60.
98. Altmann KH, Gertsch J.2007.Anticancer drugs from nature-natural products as a unique source of new microtubule-stabilizing agents[J].Nat Prod Rep,24(2):327.
99. Batist G, Barton J, Chaikin P.2002. My ocet(liposome encapsulated doxorubicin citrate):A new approach in breast cancer therapy [J]. Expert Opin Pharmacother,3(12):1739-1751.
100. Benzie IF,Strain JJ.1996.The ferric reducing ability of plasma (FRAP) as a measure of antioxidant power:the FRAP assay[J].AnalBiochem,(239):70.
101. Benzie IF,Strain JJ.1996.The ferrric reducing ability of plasma (FRAP) as a measure of antioxidant power the FRAP assay[J].Anal Biochem,(239):70.
102. Brisaert M, Gabriels M,Matthijs Vet al.2001.Liposomes tretinoin: a physical chemical evaluation [J] Pharm.Biomed.Ana.,26:909-917
103. Bryant AE 3rd,Dreifuss FE.1996.Valproic acid hepatic fatal it ies, IILU.S.experience since 1986[J].Neurology,46(2):465-469.
104. Chen AJ, Li CH, Gan WH et al.2005. Separation and determination of active components in schisandra chinensis Baill. And its medicinalpreparations by non-aqueous capillary electrophoresis.Biomedical Chromatography,19(7):481-487.
105. Chen Y G, Qin G W, Xie Y Y.2001. Lignans frome plants of schisandraceae. Chem. World, 2001(7):380-383.
106. Chiu,P.Y,Mak,D.H.F.,Poon,M.K.T.,Ko,K.M.2002.In vivo antioxidant action of alignan-enriched extract of Schisandra fruit and an anthraquinone-containing extract of Polygonum root in comparison with y-schizandrin and emodin.Planta Medics,(English),68(11):951-956.
107. Chiu,P.Y,Mak,D.H.F.,Poon,M.K.T.,Ko,K.M.2002.In vivo antioxidant action of alignan-enriched extract of Schisandra fruit and an anthraquinone-containing extract of Polygonum root in comparison with y-schizandrin and emodin.Planta Medics, (English),68(11):951-956.
108. Chiu,P.Y,Mak,D.H.F.,Poon,M.K.T.,Ko,K.M.2002.In vivo antioxidant action of alignan-enriched extract of Schisandra fruit and an anthraquinone-containing extract of Polygonum root in comparison with y-schizandrin and emodin.Planta Medics,(English),68(11):951-956.
109. CODERCH L,FONOLLOS J,DF PERA M,et al.2000.Influence of cholesterol on liposome fluidity by EPR relationshio with percutaneous absorption [J].J of Controllde Release,68:85-95.
110. Crino PB,Hong J,Melissa D.Shumate,et a 1.2002.Increased axpression of the neuronal glutamate transpoeter(EE-AT3/EAACl)in hippocampal neocortical epilepsy[J].Epilepsia,43(3):211-218.
111. Dreifuss FE,Santilli N, Langer DH, et al.1987.Valproic acid hepatic fatalities:a retrospective review [J].Neurology,37(3):379-385.
112. Elbayoumi TA,Torchilin VP.2007.Enhanced cytotoxicity of monoclonal anticancer antibody modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines[J].Eur J Pharm Sci, 32(3):159.
113. FOGLI S, NIERI P, BRESCHI M C.2004.The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage[J].FasebJ,18(6):664-75.
114. Ganzler K.1990.Microwave extraction anoval sample preparation method for chromalography[J]. Journal of Chromalography,257-262.
115. Ganzler K.1990.Microwave extraction anoval sample preparation method for chromalography[J].Journal of Chromalography,257-262.
116. Gottlieb H E, Mervic M, Ghera E J.1982. Chem Soc Perkin Trans,1982(10):2353-2358.
117. Graziadei I W,Obermoser G E,Sepp N T,et al.2003.Drug-induced lupus-like syndrome associated with severe autoimmune hepatitis[J].Lupus,12(5):409-412.
118. Grillo MP,Chiellini G.Tonelli M, et al.2001.Effect of alpha-fluorination of valp roicacid on valp royl-Sacyl-Co A formation in vivoin rats [J].Drug Metab Dispos,29 (9):1210-1215.
119. Hana trova, Petra evikova,Leona Kvasnikova, et al.2002.Detemination of lignans in Schisandra chinensis using micellar electrokinetic capillary chromatography[J]. Electr-ophoresis,23(2):253-258.
120. Hana trova,Petra evikova,Leona Kvasnikova,et al.2002.Detemination of lignans in Schisandra chinensis using micellar electrokinetic capillary chromatography[J].Electrophoresis,23(2):253-258.
121.Hana trova,Petra evikova,Leona Kvasnikova,et al.2002.Detemination of lignans in Schisandra chinensis using micellar electrokinetic capillary chromatography[J].Electrophoresis,23(2):253-258.
122. Hancke, J.L, Burgos, R.A, Ahumada, F.1999. Schisandra chinensis(Trucz.) Baill. Fitogetherapia, 70:451-471.
123. Hartmut Jaeschke, Gregory J, Gores, et al.2002.Machanisms of Hepatotoxicity[J].Toxicological Sciences,65 (2):166-176.
124. Hiroichi N, Ikuhisa Y, Motonofi A.1989. The Effect of Gomisin A on Immumlogic Liver Injury in Mice. Planta Meedic,55(1):13.
125. Huang TH,Shen PN,Shen YJ.2005.Preparative separation and purification of deoxyschisandrin and y-schisandrin from schisandra chinensis(Turcz.)Baill by high-speed counter-current chromatography[J].Journal of Chromatography A,1066(1/2):239-242.
126. Huang TH,Shen PN,Shen YJ.2005.Preparative separation and purification of deoxyschisandrin and aγ-schisandrin from schisandra chinensis(Turcz.)Baill by high-speed counter-current chromatography [J].Journal of Chromatography A,1066(1/2):239-242.
127. HuangTH,Shen PN, Shen YJ.2005.Preparative separation and purification of deoxyschisandrin and ay-schisandrin from schisandra chinensis(Turcz.)Baill by high-speed counter-current chromatography [J] Journal of Chromatography A,1066(1/2):239-242.
128. IP S P,POON M K,CHE C T,et al.1996. Γ-schizandrin protects against carbon tetrachloride toxicity by enhancing the mitochondrial glutathione redox status inmouse liver[J]. Free Radic Biol Med,2 1(5):709-712.
129. Jain KK.2000.An assessment of ralinamide as an anti-epileptic in comparison with other drugs in clinical development[J].Expert Opin Invetig Drugs,9:829-840.
130. Kadsulignan N, LIU Jin-sen, Li Liang.1995. three dibenzocy-clooctadiene lignans from kadsura coccinea. Phytochemistry,38(1):241.
131. KangDeogSung.2000.FSTA,31(8):30.
132. Kim HC,Ko KH,Kim WK,etal.2001.Effects of dextromethorphan on the seizure induced by kainite and the calcium channel agonist Bayk-8644:comparison with the effects of dextrorphan[J]. Behav brain Res,120(2):169-175.
133. Ko K M,Lam B Y H,Ko K M,Mol.2002.Cell. Boichem,238(1):181-186.
134. Ko K M,Lam B Y H,Ko K M,Mol.2002.Cell. Boichem,238(1):181-86.
135. KO K M,YIU H Y.2001. Γ-schizandrin modulates the ischemia-reperfusion induced changes in non-enzymatic antioxidant levels in isolated-perfused rat hearts[J]. Mol Cell Biochem,220 (1-2):141-147.
136. Krahenbuhl S,Mang G,Kupferschmidt H,et al.1995.Plasma and hepatic carnitine and coenzyme A pools in a patient with fatal, valproate induced hepatotoxicity[J].Gut,37(1):140-143.
137. Kuo Y H, Li SY, WuM Det al.1999. Chem. Pharm.. Bull,47(7):1047-1408.
138. Lei Zhang,Hong Pan,Min Liu.2004.In vitro and in vivo stabilities of doxorubicin aggregates with various salts insideliposomes.Acta Pharmaceutica Sinica 39(12):1018-1022
139. Li L, Lu Q, Shen Y, et al.2006.Γ-schizandrin enhances doxorubicin-induced apoptosis of cancer cells but not normal cells [J]. Biochem Pharmacol, (71):584-595.
140. Meng Sun1,Xiaoli Xu1,Qinghua Lu,Qiangrong Pan,Xun Hu,2007. Γ-schizandrin:A dual inhibitor of P-glycoprotein and multidrug resistance-associated protein 1,Cancer Letters,246:300-307
141. Meng Sun1,Xiaoli Xu1,Qinghua Lu,Qiangrong Pan,Xun Hu,2007. Γ-schizandrin:A dual inhibitor of P-glycoprotein and multidrug resistance-associated protein 1,Cancer Letters,246:300-307.
142.MINOTTI G MENNA P, SALVATORELLI E, et al.1999.Anthracyclines: molecular Modified,itll an enbancer containing insulin in rabbits[J].DrugDev.Int.Pharm.25 (10):1099-1105
143. Muramatsu K, Maitani Y,Takayama K, et al.1999.The relationship between the rigidity of the Liposomeal membrane and the absorption of in insulin after nasal administration of liposom- es modified,itll an enbancer containing insulin in rabbits[J]. Drug Dev.Int.Pharm,25(10):1099-1105.
144. MURAOKA S,MIURA T.2003.Free radicals mediate cardiac toxicity induced byadriamycin[J]. Yakugaku Zasshi,123(10):855-66.
145. Nelson RM,green AR,lambert DG,et al.2000.On the regulation of ischaemia-induced glutamte efflux from rat codex by GABA,in vitro studies with GABA,clomethiazole and pentobarbitone[J].Br J Pharmacol,130(5):1124-1130.
146. Pare J R J,Sigouin M.1991.Microwave-assisted natural products extraction.U.S.Patent,No.5002784.
147. Patel T,Bronk S.F, Gores G,J.1994.Increases of intracellular magnesium promote glycodeoxycholate-induced apoptosis in rat hepatocytes[J].J.Clin.Invest,40 (1):2183-2192.
148. Patel V B,Misra A N.1999.Encapsulation and stability of clofazimine liposomes[J].16:357-367
149. Peng JY,Fan GR, Qu LP,et al.2005.Application of preparative high-speed counter chromatography for isolation and separation of schizandrin and gomisin A from Schisandra chinensis[J].Journal of Chromatography A,1082(2):203-207.
150. Peng JY,Fan GR,Qu LP,et al.2005.Application of preparative high-speed counter chromatography for isolation and separation of schizandrin and gomisin A from Schisandra chinensis[J]. Journal of Chromatography A,1082(2):203-207.
151. Peng JY,Fan GR,Qu LP,et al.2005.Application of preparative high-speed counter chromatography for isolation and separation of schizandrin and gomisin A from Schisandra chinensis[J]. Journal of Chromatography A,1082(2):203-207.
152. PENG X,CHEN B,LIM C C,et al.2005.The cardiotoxicology of anthracycl inechemotherapeutics: translating molecular mechanism into preventative medicine[J].MolInterv,5(3):163-171.
153. Perucca E.2002.Pharmacological and therapeutic properties of valproate:a summary after 35 years of clinical experience[J].CNS Drugs,16(10):695-714.
154. Peter JE,Eduard P,Krenzelok.1999.Treatment of acetaminophen overdose[J].Am J Healdl-syst,56 (11):1081-1091.
155.Po Yee Chiu, Duncan H.F. Mak, Michel K.T. Poon, Kam Ming Ko.2005. Role of cytochrome P-450 in γ-schizandrin-induced antioxidant and heat shock responses in mouse liver. Life Sciences,77 (2005):2887-2895.
156. Po Yee Chiu,Duncan H.F. Mak,Michel K.T.Poon,Kam Ming Ko.2005.Role of cytochrome P-450in γ-schizandrin-induced antioxidant and heat shock responses in mouse liver,Life Sciences,77: 2887-2895.
157. Po Yee Chiu,Duncan H.F. Mak,Michel K.T.Poon,Kam Ming Ko.2005.Role of cytochrome P-450in γ-schizandrin-induced antioxidant and heat shock responses in mouse liver,Life Sciences,77:2887-2895.
158. Poivier V J, Thamm D H, Kurzman I D, et al.2002. Liposome encapsulated doxorubicin(doxil) and doxorubicin in the treatment of vaccine associated sarcoma in rat [J]. J. Vet. Intern. Med.,16(6): 726-731.
159. Schwarzinger C,Kranawetter H.2004.Analysis of the active compounds in different parts of the schisandra chinensis plant by means of pyrolysis-GC/MS[J].Monatshefte fur Chemie Chemical Monthly,(135):1201-1208.
160. Schwarzinger C,Kranawetter H.2004.Analysis of the active compounds in different parts of the schisandra chinensis plant by means of pyrolysis-GC/MS[J].Monatshefte fur Chemie Chemical Monthly,(135):1201-1208.
161. Su J D et al.1998.Phytochemisery,27:1315-1320.
162. SUKOWSKIA W W,PENTAK D,NOWAK K,et al.2005.The influence of temperature,cholesterol content and pH on liposome stability [J]. Journal of Molecular Structure,744-747:737-747.
163. Tian K,Qi SD,Chen YQ,et al.2005.Separation and determination of lignans from seeds of schisandra species by micellar electrokinetic capillary chromatography using ionic liquid as modifier [J].Chromatography A,1078(1/2):181-187.
164. Tian K,Qi SD,Chen YQ,et al.2005.Separation and determination of lignans from seeds of schisandra species by micellar electrokinetic capillary chromatography using ionic liquid as modifier[J].Chromatography A,1078(1/2):181-187.
165.Tober C.Rostoek A,Rundfeldt C.1996.D-23129:A potent anticonvul sant in the amygdale kindling model of complex partial seizures[J].Eur J Pharmacol,303:163-169.
166. VARVARESOU A,IAKOVOU K,GIKAS E,et al.1996.Antitumor activity of vesicle method [J].Chem:Pham.Bull.44(1):237-240
167. William M,Lee,M.D.1995.Drug-induced hepatotoxicity The New Eng[J].Journal of Medicine,333 (17): 1118-1125.
168. WOUTERS K A, KREMER L C,MILLER T L,et al.2005.Protecting against anthracycline induced myocardial damage:a review of the most promisingstrategies[J].Br J Haematol,131 (5):561-578.
169. Wu YF,Cao MF,.Gao YP,et al.2004.Down-modulation of heat shock protein 70 and up-modulantion of Caspase-3 during y-schizandrin-induced apoptosis in human hepatoma SMMC-7721 cells.Word J Gastroentrerol.(10):2944-2948
170. YIM T K KO K M.1999. Γ-schizandrin protects against myocardial ischemia-reperfusion injury by enhancing myocardial glutathione antioxidantstatus[J]. Mol CellBiochem,196 (1-2):151-156.
171. Zakim D,Thomas D.1996.Hepatology[M].Third edition,USA:WB Sanders Comtpany,962-967.
172. Zhang Shouqin, Zhu Junjie,Wang Changzhen.2004.Novel high pressure extraction technology [J].International Journal of Pharmaceutics,27(8):471.
173. Zhang Tiemei,Wang Banen,Liu Gengtao.1992.Effect of γ-schizandrin onlipoperoxidative damage to plasma memebrane of rat liver in vitro [J].Acta Pharmacologica Sinica,13(3):255-258.